

## Certificate of Analysis

<b>Cell count</b>	1.9 million per vial
<b>Viability</b>	89%
<b>CD8+</b>	98.1%
<b>CD8+HPV E7Tetramer+</b>	0.5%
<b>CD8+WT-1Tetramer+</b>	92.4%
<b>Sterility</b>	Negative for Bacteria, Yeast and Fungi
<b>Mycoplasma</b>	Negative

### *Donor Information*


<b>Donor ID</b>	398
<b>Age</b>	41
<b>Gender</b>	Female
<b>Race</b>	Caucasian
<b>Height</b>	5'6"
<b>Weight</b>	142
<b>ABO Type</b>	A positive

### *HLA typing*

	<b>Allele 1</b>	<b>Allele 2</b>
<b>HLA-A</b>	*02	*03
<b>HLA-B</b>	*07	*39
<b>HLA-C</b>	*07	*07
<b>HLA-DRB1</b>	*08	*15


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE



HPV E7(11-20) tetramer = HPV E7(11-20: YMLDLQPETT) HLA-A\*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA); WT-1 tetramer = WT-1 peptide (RMFPNAPYL)/ HLA-A\*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA)

### IFN-gamma Secretion



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 20,000 T2 cells, a B-LCL expressing HLA-A\*0201) alone or in the presence of increasing concentrations OF HLA-A\*0201 restricted CMVpp65 peptide (NLVPMVATV) or HLA-A\*0201 restricted WT-1 peptide (RMFPNAPYL). After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-γ concentration was analyzed using the Meso Scale Discovery IFN-γ assay.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE